Infectious Disease · 2006
FUTURE / Quadrivalent HPV Vaccine Efficacy Trials
Females United to Unilaterally Reduce Endo/Ectocervical Disease
Cervical cancer prevention in the early 2000s rested entirely on Pap smear screening, a secondary prevention strategy that required repeated cytological examinations over a woman's lifetime and depended heavily on health system access for its effectiveness. HPV types 16 and 18 together account for approximately 70% of cervical cancers globally, and the causal link between persistent HPV infection and cervical malignancy had been firmly established by Harald zur Hausen's work in the 1980s. The logical next step was a prophylactic vaccine targeting those types.
The scientific foundation came from Ian Frazer and Jian Zhou at the University of Queensland, who in the early 1990s developed the technology to produce virus-like particles, proteins that assembled into the structural shell of HPV without containing viral DNA. VLPs could generate a strong immune response without being infectious. Zhou died in 1999, before the vaccine reached licensure. Merck licensed the VLP platform and developed the quadrivalent formulation targeting HPV types 6, 11, 16, and 18, with types 6 and 11 responsible for most genital warts.
The FUTURE I and FUTURE II trials randomized more than 17,000 women aged 15 to 26 to the quadrivalent vaccine or placebo across multiple countries. In women who were seronegative and DNA-negative at baseline for the relevant types, the per-protocol efficacy against HPV 16/18-related CIN 2/3 or adenocarcinoma in situ reached 98% in FUTURE II. Diane Harper served as lead investigator on FUTURE II. The FDA licensed Gardasil in June 2006 on the basis of these data, making HPV the first virus linked to a major human cancer to have a licensed preventive vaccine.
The FUTURE results drew enormous attention but also early controversy. Some argued that vaccinating against types 6 and 11 alongside oncogenic types blended cancer prevention with wart prevention in a way that obscured the public health message. Others raised concerns about cost and about the ACIP recommendation for routine vaccination of girls as young as 11 or 12, before sexual debut. Diane Harper herself publicly noted that the duration of immunity was not yet established at the time of licensure, a point manufacturers and regulators subsequently addressed with longer follow-up data.
National immunization programs in Australia, the United Kingdom, and the United States began routine adolescent HPV vaccination in 2006 and 2007. Australia, which achieved high coverage early, showed measurable declines in high-grade cervical intraepithelial lesions and genital warts within a decade of program launch. The vaccine's scope expanded progressively: vaccination programs extended to boys in several countries, and a nine-valent formulation covering seven oncogenic HPV types replaced the quadrivalent version as the standard product. Cervical cancer incidence data from Australia, collected through the 2020s, have shown declines consistent with the projected impact of high population coverage.
Key People
- Ian Frazer — University of Queensland; co-developer of HPV virus-like particle technology
- Jian Zhou — Co-inventor of VLP technology underlying Gardasil; died 1999
- Diane Harper — Lead investigator, FUTURE II trial
- Harald zur Hausen — Established HPV-cervical cancer causation; 2008 Nobel laureate
- Frank Lowy — NCI researcher who contributed to early papillomavirus VLP characterization work
N Engl J Med, 2007
Related landmarks
- 2011 · HPTN 052: Antiretroviral Therapy as HIV Prevention (Infectious Disease)
- 2011 · RTS,S/AS01 (Mosquirix) Malaria Vaccine Phase 3 Trial (Infectious Disease)
- 2014 · Ledipasvir-Sofosbuvir for Hepatitis C (ION-1) (Infectious Disease)
- 1997 · ACTG 320: Triple-Drug Combination Antiretroviral Therapy (Infectious Disease)